Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel

被引：3
|
作者：
Park, Joon Oh
Kim, Seung Tae
Hong, Jung Yong
Kim, Seong-Jin
Park, Young Suk
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] GILO Fdn, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS632
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
    Jia, Ru
    Si, Hai-Yan
    Wang, Zhi-Kuan
    Deng, Guo-Chao
    Zhang, Nan
    Liu, Fang-Fang
    Shi, Yue
    Zhang, Yao-Yue
    Jia, Yu-Shan
    Wang, Yanrong
    Fan, Meng-Jiao
    Miao, Meng-Meng
    Zhang, Bei
    Tong, Shuang
    Dai, Guang-Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 671 - 671
  • [32] Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Noel, Marcus
    O'Reilly, Eileen M.
    Wolpin, Brian M.
    Ryan, David P.
    Bullock, Andrea J.
    Britten, Carolyn D.
    Linehan, David C.
    Belt, Brian A.
    Gamelin, Eric C.
    Ganguly, Bishu
    Yin, Donghua
    Joh, Tenshang
    Jacobs, Ira A.
    Taylor, Carrie T.
    Lowery, Maeve A.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 800 - 811
  • [33] Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Marcus Noel
    Eileen M. O’Reilly
    Brian M. Wolpin
    David P. Ryan
    Andrea J. Bullock
    Carolyn D. Britten
    David C. Linehan
    Brian A. Belt
    Eric C. Gamelin
    Bishu Ganguly
    Donghua Yin
    Tenshang Joh
    Ira A. Jacobs
    Carrie T. Taylor
    Maeve A. Lowery
    Investigational New Drugs, 2020, 38 : 800 - 811
  • [34] A Phase 1/1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
    Lowery, Maeve A.
    Yu, Kenneth H.
    Kelsen, David Paul
    Harding, James J.
    Bomalaski, John S.
    Glassman, Danielle C.
    Covington, Christina M.
    Brenner, Robin
    Hollywood, Ellen
    Barba, Adalberto
    Johnston, Amanda
    Liu, Kay Chia-Wei
    Feng, Xiaoxing
    Capanu, Marinela
    Abou-Alfa, Ghassan K.
    O'Reilly, Eileen M.
    CANCER, 2017, 123 (23) : 4556 - 4565
  • [35] First-line liposomal irinotecan (nal-IRI), oxaliplatin and S-1 (NASOX) in unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase I/II study
    Yoo, C.
    Kim, B.
    Lee, C.
    Kim, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S164 - S164
  • [36] Eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent nab-paclitaxel plus gemcitabine (NG) versus FOLFIRINOX (FIO)
    Peixoto, Renata D'Alpino
    Renouf, Daniel John
    Lim, Howard John
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [37] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
    Cartwright, Thomas H.
    Parisi, Monika
    Espirito, Janet L.
    Wilson, Thomas
    Pelletier, Corey
    Patel, Manish
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
    Jin, Gang
    Guo, Shiwei
    Zhang, Yanqiao
    Ma, Yue
    Guo, Xiaodong
    Zhou, Xiaocui
    Yu, Qin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel/gemcitabine
    Sunil, Hingorani
    Andrea, Bullock
    Tara, Seery
    Lei, Zheng
    Darren, Sigal
    Paul, Ritch
    Fadi, Braiteh
    Mark, Zalupski
    Nathan, Bahary
    William, Harris
    Jie, Pu
    Carrie, Aldrich
    Sihem, Khelifa
    Wilson, Wu
    Joaquina, Baranda
    Ping, Jiang
    Andrew, Hendifar
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    ONCOLOGIST, 2023, 28 (07): : E575 - E584
12345